US HHS starts distributing donated remdesivir supplies

11 May 2020

On Saturday, the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced the allocation plan for the drug remdesivir.

Gilead Sciences (Nasdaq: GILD) committed to supplying approximately 607,000 vials of the experimental drug over the next six weeks to treat an estimated 78,000 hospitalized COVID-19 patients under the Emergency Use Authorization ( EUA) granted by the Food and Drug Administration. The donation to the USA is part of 1.5 million vials of remdesivir the company is donating worldwide., under the trade name

Since the US grant for emergency use, remdesivir has also been granted ‘exceptional’ use, under the trade name Veklury, by the Japanese regulator.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK